Meetings & Events

Benefits of Diabetes Agents: Beyond Blood Glucose

July 21, 2020

Session Description: There is growing evidence to support benefits of antidiabetic therapy beyond glycemic lowering. Recent guidelines include consideration of underlying comorbidities including obesity, renal, cardiovascular, and non-alcoholic fatty liver disease in individualizing treatment regimens for our patients. Our colleagues in cardiology and nephrology have also begun to prescribe these medications for risk modification beyond glycemic control. A thorough understanding of the evidence to support recent guidelines is essential to designing treatment regimens to successfully achieve glycemic targets while modifying the risk associated with comorbid conditions.

Faculty: Jennifer Green, MD
Duke University

Learning Objectives:

  1. Describe the efficacy and safety of SGLT-2 inhibitor therapy in patients with renal and cardiovascular disease, and heart failure.
  2. Discuss the evidence to support GLP-1 receptor agonist therapy in patients with cardiovascular and renal disease.
  3. Apply the evidence for use of GLP-1 receptor agonist therapy in patients with obesity and non-alcoholic fatty liver disease.

Return to the full CEU program.

Last Updated:
Back to top
Short on time?

We'll come to you...

Get updates on the latest breakthroughs, clinical practice guidelines, and career development opportunities, straight to your inbox

Then take the next step: Set up your free website account and get exclusive access to even more great tools & content!